Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

3cb42f23-0644-4822-a504-374b264eb64e - samples

ABSTRACT: Raw FASTQ files obtained by RNA sequencing of tumor samples from patients (age 12-29) with newly diagnosed, recurrent intermediate or high-grade sarcoma.

PROVIDER: EGAD00001008393 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

RP1759 AYA sarcoma methylation array

Project description:Raw methylation array data for tumor samples from patients with newly diagnosed, recurrent intermediate or high-grade sarcoma.

| EGAD00010002275 | EGA

baab85b9-3c5b-4ca5-9898-207ca32cdbe8 - samples

Project description:Raw FASTQ files obtained from whole exome sequencing (WES) of normal samples from patients with newly diagnosed, recurrent intermediate or high-grade sarcoma.

| EGAD00001008405 | EGA

8685ca5f-b1c5-474a-9186-8fb190000689 - samples

Project description:Raw FASTQ files obtained from whole exome sequencing (WES) of tumor samples from patients with newly diagnosed, recurrent intermediate or high-grade sarcoma.

| EGAD00001008394 | EGA

SPECTA RP-1759-AYA Sarcoma cohort

Project description:EORTC-SPECTA RP1759 study focuses on cancers in adolescent and young adult (AYA), age 12 to 29 years. This study explicitly recruited AYA patients and therefore collected empirical data to bridge the molecular gap between pediatric and adult oncology. The initial pilot study, activated in February 2019 across Europe, aimed to recruit 100 AYA patients (aged 12-29 years) with newly diagnosed or relapsed high-grade gliomas and high-grade bone and soft tissue sarcomas. The primary objective of the pilot is to determine feasibility and recruitment rates. Here we submit the data from patients with newly diagnosed, recurrent intermediate or high-grade sarcoma that were collected and analyzed during the study. More specifically, we submit raw FASTQ files obtained from whole exome sequencing (WES) of matching tumor and blood samples, tumor RNA sequencing and DNA methylation profiling.

| EGAS00001005840 | EGA

Copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia

Project description:Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients. Single nucleotide polymorphism (SNP)-arrays allow simultaneous detection of copy-number aberrations (CNAs) and copy-number neutral loss-of-heterozygosity (CNN-LOH). In this study we investigated the presence of CNAs and CNN-LOH in newly diagnosed CLL samples from a Swedish chronic lymphocytic leukemia (CLL) cohort. In this study we could detect the known recurrent aberrations in CLL (i.e. deletions of 13q, 11q, 17p and trisomy 12). We also detected other both large and small CNAs which were mostly non-recurrent. CNN-LOH was detected on chromosome 13q in patients that carried homozygous deletion of 13q.

2009-11-23 | GSE16406 | GEO

Affymetrix SNP array data for Chronic Lymphocytic Leukemia_diagnostic sample_patient samples

Project description:High-resolution genomic microarrays provides simultaneous detection of copy-number aberrations such as the known recurrent aberrations in Chronic Lymphocytic Leukemia_diagnostic sample_patient (del(11q), del(13q), del(17p) and trisomy 12), and copy-number neutral loss of heterozygosity. We screened 369 newly diagnosed Chronic Lymphocytic Leukemia_diagnostic sample_patient patient samples from a population-based cohort using 250K single nucleotide polymorphism-arrays.

2011-04-28 | GSE28030 | GEO

Mucosal gene expression profiling in ileum of patients with Crohn's disease

Project description:In this study, we investigated gene expression profiles in ileal mucosa from CD patients in different settings (post-operative CD (Rutgeerts score i0); post-operative recurrent CD (i1), post-operative recurrent CD (≥i2b), newly diagnosed CD and late stage CD)) and controls.

2019-03-01 | GSE102133 | GEO

Affymetrix SNP array data for Chronic Lymphocytic Leukemia_diagnostic sample_patient samples

2011-04-28 | E-GEOD-28030 | biostudies-arrayexpress

Intratumoral heterogeneity and longitudinal changes in gene expression predict differential drug sensitivity in newly diagnosed and recurrent glioblastoma

Project description:We investigated longitudinal transcriptomic patterns associated with glioblastoma (GB) recurrence by integrative approach utilizing multisampling strategy, RNA sequencing and complementary investigations of tumor tissues and GB stem cells. In total, 128 tissue samples of 44 tumors including 23 first diagnosed, 19 recurrent and 2 secondary recurrent GBs were analyzed in parallel with 27 primary cultures of GB stem cells. We found that intratumoral transcriptomic heterogeneity is an intrinsic characteristic that is conserved in newly diagnosed and recurrent GBs and captured in GB stem cells. We revealed a high degree of concordance between GB tumor tissues and stem cells in the longitudinal transcriptomic changes associated with tumor recurrence. We used gene expression data to model the efficacy of 130 anti-cancer drugs. For the recurrent tumor tissues and isolated GB stem cells we showed dramatically reduced simulated sensitivities to the first line chemotherapeutic temozolomide. In turn, several therapeutics including immune checkpoint inhibitors were predicted to be more effective in the recurrence setting. Our results strongly suggest that the spectrum of potentially effective drugs may differ between newly diagnosed and recurrent glioblastomas and provides a transcriptional rationale for the lack of significant therapeutic benefit from temozolomide in patients with recurrent GB.

2020-03-01 | GSE139533 | GEO

Mucosal miRNA expression profiling in ileum of patients with Crohn's disease

Project description:In this study, we investigated miRNA expression profiles in ileal mucosa from CD patients in different settings (post-operative recurrent (POR) CD, newly diagnosed CD and late stage CD)) and controls.

2019-03-01 | GSE102127 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data